Failure to Satisfy Listing Rule Form 8 K

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On November 4, 2024, Novo Integrated Sciences, Inc. (the "Company") received a letter from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company's common stock will be delisted from Nasdaq and trading in the Company's common stock will be suspended at the open of trading on November 6, 2024. As previously reported, the Nasdaq Listing Qualifications Staff (the "Staff") notified the Company that it was in violation of the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Beginning at the open of trading on November 6, 2024, trading of the Company's common stock is expected to continue on the OTC Market under the symbol "NVOS."